Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
The Lancet. Haematology|November 9, 2024
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trialPratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, et al.
Polski Przeglad Chirurgiczny|December 15, 2011
Recommendations for the management of trauma or surgery-related massive blood lossPiotr Paluszkiewicz, Ewa Mayzner-Zawadzka, Włodzimierz Baranowski, et al.
Research and Practice in Thrombosis and Haemostasis|October 26, 2022
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare diseaseErika Tarasco, Anne Sophie von Krogh, Radomira Hrdlickova, et al.
The New England Journal of Medicine|August 30, 2023
Phase 3 Trial of Concizumab in Hemophilia with InhibitorsTadashi Matsushita, Amy Shapiro, Aby Abraham, et al.
The New England Journal of Medicine|May 1, 2024
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic PurpuraMarie Scully, Ana Antun, Spero R Cataland, et al.
Hemasphere|March 26, 2025
Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotypeFrancesco Rodeghiero, Lisanna Ghiotto, Luca Pontalto, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2021
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitorsMiguel Escobar, James Luck, Yevhenii Averianov, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 27, 2022
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitorsSteven W Pipe, Cédric Hermans, Meera Chitlur, et al.
Hepatology (Baltimore, Md.)|September 13, 2019
EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent AttacksLaurent Gouya, Paolo Ventura, Manisha Balwani, et al.
The New England Journal of Medicine|June 11, 2020
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent PorphyriaManisha Balwani, Eliane Sardh, Paolo Ventura, et al.
Pageof 10